Diabetic foot ulcers (DFU) are complications in diabetes mellitus (DM) that can lead to amputations of limbs. The number of DFU predicted about 25% from the total of DM patients. Platelet-rich plasma (PRP) therapy plays an important role to manage DFU due to the high content of bioactive molecules. PRP can be obtained and processed by whole blood followed by activation to release growth factors. Therefore, autologous activated PRP (aaPRP) therapy may be a potential candidate to cure DFU. In this review, we addressed the mechanism of DFU, PRP characterization, in vitro and animal studies of PRP, PRP therapy to treat DFU, and clinical trials of DFU using PRP.